CA2111340C - Novel polypeptides and their use - Google Patents
Novel polypeptides and their use Download PDFInfo
- Publication number
- CA2111340C CA2111340C CA002111340A CA2111340A CA2111340C CA 2111340 C CA2111340 C CA 2111340C CA 002111340 A CA002111340 A CA 002111340A CA 2111340 A CA2111340 A CA 2111340A CA 2111340 C CA2111340 C CA 2111340C
- Authority
- CA
- Canada
- Prior art keywords
- pro
- arg
- phe
- polypeptide according
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
A polypeptide comprising the following amino acid sequence: Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro; and function-al derivatives thereof; pharmaceutical compositions containing such polypeptides; and a method of inhibiting bacterial growth.
Description
~~1_~~. ~~~~
Novel polvceptides and their use.
The present invention relates to new polypeptades ha-ving bacteriocidal activity in that they are capable of kil-ling certain bacteria, particularly gram-negative ones. The invention also covers pharmaceutical compositions and methods of use for the inhibition of bacterial growth.
The small intestine is an important endocrine organ and a number of physiologically active peptides have been initially isolated from porcine tissue (Mutt, V., Chemica Scripta 26B, 191-207 (1986)). During normal healthy condi-tions, the upper part of the small intestine contains few bacteria. Below the duodenum the concentration of bacteria progressively increases until the maximum, 1011 bacteria per g of feces, is reached in~the large intestine. It is remark-i5 able that such a mass of bacteria can coexist with a delicate host organ. Small bnsic peptides called cecropins play an important role in insect immunity CBoman, H.G. 8 Hultmark, D., D,Ann.Rev.Microbiol. 41, 103-126 (1987)) and structurally unrelated peptides called magainins CZasloff, M., Proc.Natl.
Acad.Sci. USA, 84, 5449°5453 (1987)) proteet the frog skin from infections. Another group of antibacterial peptides, the defensins were first isolated from mammalian granulocytes (Selstedt, M.B., Szklarek, D. S Lehrer, R.I. Infect.Iaunun.
45, 150-154 (1984)) and neutrophils CSelstedt, M.E., Hrown, D.M., DeLange, R.J., ~2arwig, S.S. 8 Lehrer, R.I., J.Hiol.
Chem. 260, 4579-4584 11985)) and recently also from insects (Matsuyama, K. 8 Natori, S. J.Biol.Chem. 263, 17112-17116 (1988>; Lambert, J. et al. Froc.Natl.Acad.Sci. USF, 86, 262°
-266 (1989)). In addition, bovine neutrophils have been found to contain bactenecins (Romeo, D " Skerlavaj, B., Bolognesi, M & Gennaro, R. J.Biol.Chem. 263, 9573-9575 (1388>, another small basic peptide. Bath defensina and the small bacteneein contain one or more disulfide bridges while cecropins and magainins are cysteine-free. Frank et. al (J. Biol. Chem.
265:18871-18874) have described two large bactenicins with high contents of proline and arginine and without cystei,ne.
The present inv~entian has for an object to provide new suBSTaTU~r~ sH~~T
.«
.. . .. .. .. ... ~.. ..~. . . ... ... ... ._ .. ....::..~. _~.. :~ ~. . ; _ .
Novel polvceptides and their use.
The present invention relates to new polypeptades ha-ving bacteriocidal activity in that they are capable of kil-ling certain bacteria, particularly gram-negative ones. The invention also covers pharmaceutical compositions and methods of use for the inhibition of bacterial growth.
The small intestine is an important endocrine organ and a number of physiologically active peptides have been initially isolated from porcine tissue (Mutt, V., Chemica Scripta 26B, 191-207 (1986)). During normal healthy condi-tions, the upper part of the small intestine contains few bacteria. Below the duodenum the concentration of bacteria progressively increases until the maximum, 1011 bacteria per g of feces, is reached in~the large intestine. It is remark-i5 able that such a mass of bacteria can coexist with a delicate host organ. Small bnsic peptides called cecropins play an important role in insect immunity CBoman, H.G. 8 Hultmark, D., D,Ann.Rev.Microbiol. 41, 103-126 (1987)) and structurally unrelated peptides called magainins CZasloff, M., Proc.Natl.
Acad.Sci. USA, 84, 5449°5453 (1987)) proteet the frog skin from infections. Another group of antibacterial peptides, the defensins were first isolated from mammalian granulocytes (Selstedt, M.B., Szklarek, D. S Lehrer, R.I. Infect.Iaunun.
45, 150-154 (1984)) and neutrophils CSelstedt, M.E., Hrown, D.M., DeLange, R.J., ~2arwig, S.S. 8 Lehrer, R.I., J.Hiol.
Chem. 260, 4579-4584 11985)) and recently also from insects (Matsuyama, K. 8 Natori, S. J.Biol.Chem. 263, 17112-17116 (1988>; Lambert, J. et al. Froc.Natl.Acad.Sci. USF, 86, 262°
-266 (1989)). In addition, bovine neutrophils have been found to contain bactenecins (Romeo, D " Skerlavaj, B., Bolognesi, M & Gennaro, R. J.Biol.Chem. 263, 9573-9575 (1388>, another small basic peptide. Bath defensina and the small bacteneein contain one or more disulfide bridges while cecropins and magainins are cysteine-free. Frank et. al (J. Biol. Chem.
265:18871-18874) have described two large bactenicins with high contents of proline and arginine and without cystei,ne.
The present inv~entian has for an object to provide new suBSTaTU~r~ sH~~T
.«
.. . .. .. .. ... ~.. ..~. . . ... ... ... ._ .. ....::..~. _~.. :~ ~. . ; _ .
2~1~1~~
WO 92/22578 ~ ~ ~ PCi'/SE92/00394~
bactericidal polypeptides eapable of inhibiting bacterial growth, in pa,rticula: the g:owth of gram negative bacteria.
In this disclosure the term "inhibiting" also includes the killing of bacteria.
Another object of the invention is to provide composi-tions containing as an active constituent such poly.peptides.
Yet another object of the invention is to provide a method of treatment directed to inhibition of bacterial growth in animals, in particular mammals including man.
I0 For these and other objects wich will be clear from the following disclosure the invention provides n polypeptids having the amino acid sequence:
~' Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-?ro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro--Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro, and the invention also includes functional derivatives such as a few conservative amino acid replacements and the C-terminal amide. .
The polypeptide of the present invention and its func-tional derivatives are all therapeutically useful, particu-larly as antibacterial agents. Thus, they are capable of in-hibiting growth of bacteria or killing bacteria, in particu-lar gram-negative bacteria making them useful for different therapeutic purposes. This will 'be further illustrated by specific examples which are given below.
The active polypeptide according to the present inven-tion can be formulated for use in human or veterinary mediei-ne for therapeutic or profylactic use. The active prepare-Lions are normally~administered orally, rectally or parente-rally,~such as by injection in the form of a pharmaceutical preparation or composition comprising the active constituents in combination with a pharmaceutically acceptable carrier which may be solid, semi-solid or liquid, or contained in a capsule, such as when orally administrered. The administra-tion may also take the form of topical application. As examp-les of pharmaceutical preparations there may be mentioned SUBSTITUTE SHEET
~1:~_~a4~
WU 92/22578 PC'I'/SE92/00394 tablets, drops, solutions and suppositories. Usually, the active constituent constitutes the minor part of the prepara-tion, such as from nbout'0.1 to about 50~ thereof based on weight.
In order to prepare pharmaceutical compositions in the form of dose units for oral application the polypeptide of the invention can be mixed with a solid, pulverulent or other carrier, for example. lactose, saccharose, sorbitol, mannitol, starch, such as potat~e starch, corn starch, millopectine, cellulose derivative or gelatine, and may also include-lubri-cants, such as magnesium or calcium stearate, or'polyethylens glycol waxes compressed to the formation of tablets or bodies for drag~es. The dose units may also be presented in a coated form of enteric type.
By~using several layers of the carrier or diluent tab-lets operating with slow release can be prepared.
Liguid preparations for oral application or for injec-tion can be made in the form of elexirs, syrups or suspen-sions, for example solutions containing from 0.1 to 20~ by weight of active suba~tance, sugar and a mixture of ethanol, water, glycerol, propyleneglycol and possibly other additives of a conventional natur~.
The doss by which the active constituent is administe red may vary within wide limits and is dependent on different factors, such as the seriousness of the disorder, the age and the weight of the patient and can be adjusted individually.
The invention also covers a method for therapeutic treatment of animals, such as mammals including man, said method comprising the step of administering a polypeptide as described above or a functional derivative thereof in an a-mount capable of killing bacteria or inhibiting bacterial growth in said animal.
The present invention will now be further exemplified by specific examples which, however, are not to be construed as limiting the scope of the invention otherwise than accord ding to the appended claims.
~vBS-re~u~~ ~~~s~~
_____..___._______~___....._._...~.n~.r.~.... ..r _..,.~.. ....-, .n. m..
....,__ ....r...... n. ... .r.r.:.;:,.W .ES.:.f.r.;...s.~l~:...; ;5.,-Wqs;.
'~:..;y:..~';1~: t_ :.,.,i.,... ._ ......
WO 92/22578 PCl'/SE92/00394 G
"EXAMPLE 1 pronaratien of a oeot~de concentrate A concentrate of thermostable intestinal peptides was prepared from pig small intestine essentially as described elsewhere (Mutt, V. Arkiv Kemi ~, 69-74 (1959); mutt, y'. in Gut Hormones (ed. Bloom,.S.R.), pp 21-27, (Churchill Living-stone, Edinburg, 1978).
Briefly, the uppermost meter of the intestine was im-messed far 8 t 1 min into boiling water and then cooled on ice and frozen. The frozen material was minced and extracted at 0-l5oC with 0.5 M acetic acid for 1~2 h and the mixture filtered with suction (with the aid of "Hyflo Super-Cel", 30 g per liter suspension). Peptides were adsorbed from the fil-trats to alginic acid and the alginic acid carrying the pep-tides~ was washed in turn with 0.005 M HCl, 95x ethanol (to remove fats) and 0.005 M HC1 again. The peptides were eluted with 0.2 M ice-cold HCl and the pH of the eluate was brought to 3.5 ~ 0.1 with sodium acetate. Peptides were then precipi-tated by saturating the eluate with NaCl, and the precipitate Was collected by suction filtration. The amount by weight of the precipitate (wet weight) is about one thousandth, of that of the boiled intestinal tissue.
The concentrate was dissolved at room temperature to s 10~ w/v solution in water. Two volumes of 95~ ethanol were added to the solution and the (apparent) pH tae measured with a glass electrode) of it was brought to 7.5 ~ 0.1 with NaOH
(1M NaOH:EtOH 1:2). A precipitate formed and was removed by filtration. To the clear solution one volume of 95X ethanol precooled to -20oC was added and the suspension was kept at this temperature for 24 h whereupon it w.ae filtesed. The pep-tides were recovered from the filtrate in aqueous solution and precipitated at pH 3.5 t 0.1 by saturation of the solu-tion with NsCl. The precipitate, collected by suction filtra-Lion, weighed about lOX of that of the concentrate taken for its preparation. It was dissolved in 0.2 M AcOH and chromato-SUBSTITUTE SHEET
graphed in this solvent on Sephadex* G-25 fine. The second half by volume of the peptide containing eluate from this chromatography was saturated with NaCl and the precipitate collected by suction filtration. Its weight was about 40%
5 of that of the peptide precipitate taken for this chromatography. It was dissolved in water, the pH of the solution was adjusted to 4 ~ 0.1 whereupon the peptides were reprecipitated with NaCl and the precipitate collected by suction (there was no significant difference in weight of the material before and after reprecipitation). The reprecipitated material was extracted with methanol (50 ml/g) and the MeOH-insoluble fraction was collected by suction filtration and washed on the filter with ether. The ether was evaporated in vacuo. The weight of the dry material was about 15% of that of the peptide precipitate taken for extraction with MeOH.
wTrrtr~r n ~
Purification of concentrate As a starting material for the purification there was used the concentrate resulting from Example 1. The concentrate (1.5 g) was dissolved in 80 ml ammonium formate, pH 6.4, and treated with 30 ml of DEAE Sepharose*, batch-m se.
Step 1: Chromatography on CM-Sepharose* CL-6B (56 ml column, equilibrated with 0.1 M ammonium formate, pH 6.4).
Elution was initially carried out with 0.1 M ammonium formate (about 2100 ml) to a low extinction and then gradient elution was performed using 0.1-0.85 M ammonium acetate, pH 5.2 (300 + 300 ml). The activity leaves as an * Trademark 5a integral peak having a maximum at 0.38 M, specific activity 30-40 units/~g. (1 unit is defined as the activity of lng of cecropin A.) The fraction showing the highest antibacterial activity was chosen for further purification.
z~~~J~
WO 92/22578 PCT/SE92/0039~ ':
g Step 2: Further purification of cSCMC fraction PSCMC fraction was dissolved in 8 mg/ml H20. SO~,tl of.sampla (0.4 mg) was mixed with 450 ~l O.iX TFA in water and applied on a FPLC coupled Pep RPC HR5/5 (Pharmacia). The column was washed with O.iX TFA in H20 for 10 min. at a flow rate of 0.5 ml/min. Then the acetonitrile concentration was raised to 27X
in 5 min. The~active material was eluted with a gradient of 27X-32X acetonitrile in 34 min. An aliquot t50 ~.tl or i00 ~1) of each fraction was dried in the Spesdvac and dissolved in i0 10~.t1 H20 and 3 ~1 was used in an antibacterial assay.
Result: The active material was eluted at 28.5X acetonitrils under tt-.e chosen gradient profile. On the appended drawing there is shown,a diagram on antibacterial activity (E.coli) i5 as a function of elut3on.tims. As a test sample there was used 0 . 4 mg of the purif isd active f raction in 50 Etl H20 mixed with 450 ~.tl of O.iX TFA in H20. The sample was applied to Pep RPC HR5/5 coupled to FPLC. The elution program was as follows:
dime X~acetonitrzle i5 27 Antibacterial assay The antibacterial activity of the polypeptide of this invention was determined by inhibition zone assay as descri-bed by Hultmark et al. (Hultmark, D., ~ngstrom, A., Anderson, K., Steiner, H., Hennich, H. and Homan, H.G. C1983). Inswct immunity. Attacins, a family of antibacterial proteins from a cec-"rooia . EMBO J . 2 , 571-576 ) .
SUBSTITUTE SHEET
Log-phase bacteria were grown to a density of 100 units on a Klett-summerson photoelectric colorimeter. Thev were diluted 50 times with LB medium and 50 ~l of the bacteria suspension was mixed with 6 ml of 1.0% agarose in LB medium (w/v) and poured on the petri dishes (Falcon 1001 Optilux*) with inner diameter 8.65 cm. For E.coli this procedure will give about 2 x 105 bacteria per plate.
The plates were left for 1 hour at room temperature, and holes with 3mm diameter were made on the solidified agarose. 100 ~l of fractions were dried in a speedvac and dissolved in 10 ~1 H20, of which 3 ~1 was applied to the holes. After 30 min diffusion time the plates were incubated at 30°C overnight. The diameter of the inhibition zones were measured and the relative unit activity was calculated from a standard curve which was constructed on varying amount of Cecropin A versus activity.
One microgram of Cecropin A corresponds to 1000 units of activity.
The anti-E.coli activity of PS CMC fractions Fraction No. Specific activity (units/~g) PS CMC Fr. I 0.5 PS CMC Fr. II 0_7 PS CMC Fr. III 1.4 PS CMC Fr. IV 2.0 PS CMC Fr. V 14.0 PS CMC Fr. VI 84.0 PS CMC Fr. VII 100.0 *Trademark WO 92/22578" 1 1 ~ 3 4 ~ pCT/5E92/003~
The anti-E c~~~ ~~t:~:tyof fractions collected from the re-vs~~ a n11~:~ f~hrn~nwtneran1v of PS CMC Fr. VII On a FPLC COllD"
led Pe~RPC HR5/5 column.
Frac tion No. ~ Unit activity/traction Fr. i-8 activity not detestable Fr. 9 8400 Fr. i0 28000 Fr. ii 28000 Fr. 12 13000 Fr. 13 7300 Fr. i4 3500 Fr. i5 1100 Fr. 16-30 activity not detectable In this test 400 E,tg PS CMC Fr. VII was applied to the column.
Example 3 was rspeated by using $~,il.lus meaaterium for measuring the antibacterial activity of the present poly-peptide. The experiment has shown that Hacil~ug meaaiterium is more sensitive than coli to the peptide,~the average acti-vity of the polypeptide being about 3 times higher than in relation to ~'.,~coli.
SUBSTITd.lTF SHEET
__ _--~_ .~~~~....~~......w.............'.<.,......e~wmP~r.mr..K.eam~nxn~.<a.mc...
.~.r, eu.<,h... x~.. !..as .,5~4~:k4~....~AntP'.'S'.-r~'v~y~.,.,..i.rs(k:.;a5'f'~S' . 41n 1 1S. , ...a.. ,. ,.... . ' ' ~ ~ ~ ~ ~ ~ ~ PCT/SE92/00394 9 :,~. .
inhibition zone otide on di,~fe rent bacteria assay of PR-ne Qraanism Strain bax zone fm m) L,C value tuM) Escherichia coli K12 D21 18,3 0,3 Eschericliia coli Bd2221/75 0,3 17,6 Salmonella typhimurium L12 15,2 1 Proteus vulgaris Pvii - 3,5 300 Pseudomones aeruginose OT97 4,5 200 Acinetobacter '- calcoaceticus Acii 12,5 3 i5 Bacillus megaterium Hmii 17,4 0,3 Bacillus subtilis 10,3 15 Hsii Staphylococcus aureus Cowan 1 3,7 200 Streptococcus - pyrogenes - 14,9 2 The maximum concentration ide was 2,5 mM
of PR-pept and 3~1 was applied to each well in thin agaros e plates seeded with test bacte rium. LV values from a dilution are obtained aerie and is th e lowest concentration givin g killing tHultmark, D., Engstrom, Anderson, K., Steiner, H., A., Hennich, H. and Boman, H.G. (19a3)) SUBSTITUTE SHEET
WO 92/22578 ~ ~ ~ PCi'/SE92/00394~
bactericidal polypeptides eapable of inhibiting bacterial growth, in pa,rticula: the g:owth of gram negative bacteria.
In this disclosure the term "inhibiting" also includes the killing of bacteria.
Another object of the invention is to provide composi-tions containing as an active constituent such poly.peptides.
Yet another object of the invention is to provide a method of treatment directed to inhibition of bacterial growth in animals, in particular mammals including man.
I0 For these and other objects wich will be clear from the following disclosure the invention provides n polypeptids having the amino acid sequence:
~' Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-?ro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro--Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro, and the invention also includes functional derivatives such as a few conservative amino acid replacements and the C-terminal amide. .
The polypeptide of the present invention and its func-tional derivatives are all therapeutically useful, particu-larly as antibacterial agents. Thus, they are capable of in-hibiting growth of bacteria or killing bacteria, in particu-lar gram-negative bacteria making them useful for different therapeutic purposes. This will 'be further illustrated by specific examples which are given below.
The active polypeptide according to the present inven-tion can be formulated for use in human or veterinary mediei-ne for therapeutic or profylactic use. The active prepare-Lions are normally~administered orally, rectally or parente-rally,~such as by injection in the form of a pharmaceutical preparation or composition comprising the active constituents in combination with a pharmaceutically acceptable carrier which may be solid, semi-solid or liquid, or contained in a capsule, such as when orally administrered. The administra-tion may also take the form of topical application. As examp-les of pharmaceutical preparations there may be mentioned SUBSTITUTE SHEET
~1:~_~a4~
WU 92/22578 PC'I'/SE92/00394 tablets, drops, solutions and suppositories. Usually, the active constituent constitutes the minor part of the prepara-tion, such as from nbout'0.1 to about 50~ thereof based on weight.
In order to prepare pharmaceutical compositions in the form of dose units for oral application the polypeptide of the invention can be mixed with a solid, pulverulent or other carrier, for example. lactose, saccharose, sorbitol, mannitol, starch, such as potat~e starch, corn starch, millopectine, cellulose derivative or gelatine, and may also include-lubri-cants, such as magnesium or calcium stearate, or'polyethylens glycol waxes compressed to the formation of tablets or bodies for drag~es. The dose units may also be presented in a coated form of enteric type.
By~using several layers of the carrier or diluent tab-lets operating with slow release can be prepared.
Liguid preparations for oral application or for injec-tion can be made in the form of elexirs, syrups or suspen-sions, for example solutions containing from 0.1 to 20~ by weight of active suba~tance, sugar and a mixture of ethanol, water, glycerol, propyleneglycol and possibly other additives of a conventional natur~.
The doss by which the active constituent is administe red may vary within wide limits and is dependent on different factors, such as the seriousness of the disorder, the age and the weight of the patient and can be adjusted individually.
The invention also covers a method for therapeutic treatment of animals, such as mammals including man, said method comprising the step of administering a polypeptide as described above or a functional derivative thereof in an a-mount capable of killing bacteria or inhibiting bacterial growth in said animal.
The present invention will now be further exemplified by specific examples which, however, are not to be construed as limiting the scope of the invention otherwise than accord ding to the appended claims.
~vBS-re~u~~ ~~~s~~
_____..___._______~___....._._...~.n~.r.~.... ..r _..,.~.. ....-, .n. m..
....,__ ....r...... n. ... .r.r.:.;:,.W .ES.:.f.r.;...s.~l~:...; ;5.,-Wqs;.
'~:..;y:..~';1~: t_ :.,.,i.,... ._ ......
WO 92/22578 PCl'/SE92/00394 G
"EXAMPLE 1 pronaratien of a oeot~de concentrate A concentrate of thermostable intestinal peptides was prepared from pig small intestine essentially as described elsewhere (Mutt, V. Arkiv Kemi ~, 69-74 (1959); mutt, y'. in Gut Hormones (ed. Bloom,.S.R.), pp 21-27, (Churchill Living-stone, Edinburg, 1978).
Briefly, the uppermost meter of the intestine was im-messed far 8 t 1 min into boiling water and then cooled on ice and frozen. The frozen material was minced and extracted at 0-l5oC with 0.5 M acetic acid for 1~2 h and the mixture filtered with suction (with the aid of "Hyflo Super-Cel", 30 g per liter suspension). Peptides were adsorbed from the fil-trats to alginic acid and the alginic acid carrying the pep-tides~ was washed in turn with 0.005 M HCl, 95x ethanol (to remove fats) and 0.005 M HC1 again. The peptides were eluted with 0.2 M ice-cold HCl and the pH of the eluate was brought to 3.5 ~ 0.1 with sodium acetate. Peptides were then precipi-tated by saturating the eluate with NaCl, and the precipitate Was collected by suction filtration. The amount by weight of the precipitate (wet weight) is about one thousandth, of that of the boiled intestinal tissue.
The concentrate was dissolved at room temperature to s 10~ w/v solution in water. Two volumes of 95~ ethanol were added to the solution and the (apparent) pH tae measured with a glass electrode) of it was brought to 7.5 ~ 0.1 with NaOH
(1M NaOH:EtOH 1:2). A precipitate formed and was removed by filtration. To the clear solution one volume of 95X ethanol precooled to -20oC was added and the suspension was kept at this temperature for 24 h whereupon it w.ae filtesed. The pep-tides were recovered from the filtrate in aqueous solution and precipitated at pH 3.5 t 0.1 by saturation of the solu-tion with NsCl. The precipitate, collected by suction filtra-Lion, weighed about lOX of that of the concentrate taken for its preparation. It was dissolved in 0.2 M AcOH and chromato-SUBSTITUTE SHEET
graphed in this solvent on Sephadex* G-25 fine. The second half by volume of the peptide containing eluate from this chromatography was saturated with NaCl and the precipitate collected by suction filtration. Its weight was about 40%
5 of that of the peptide precipitate taken for this chromatography. It was dissolved in water, the pH of the solution was adjusted to 4 ~ 0.1 whereupon the peptides were reprecipitated with NaCl and the precipitate collected by suction (there was no significant difference in weight of the material before and after reprecipitation). The reprecipitated material was extracted with methanol (50 ml/g) and the MeOH-insoluble fraction was collected by suction filtration and washed on the filter with ether. The ether was evaporated in vacuo. The weight of the dry material was about 15% of that of the peptide precipitate taken for extraction with MeOH.
wTrrtr~r n ~
Purification of concentrate As a starting material for the purification there was used the concentrate resulting from Example 1. The concentrate (1.5 g) was dissolved in 80 ml ammonium formate, pH 6.4, and treated with 30 ml of DEAE Sepharose*, batch-m se.
Step 1: Chromatography on CM-Sepharose* CL-6B (56 ml column, equilibrated with 0.1 M ammonium formate, pH 6.4).
Elution was initially carried out with 0.1 M ammonium formate (about 2100 ml) to a low extinction and then gradient elution was performed using 0.1-0.85 M ammonium acetate, pH 5.2 (300 + 300 ml). The activity leaves as an * Trademark 5a integral peak having a maximum at 0.38 M, specific activity 30-40 units/~g. (1 unit is defined as the activity of lng of cecropin A.) The fraction showing the highest antibacterial activity was chosen for further purification.
z~~~J~
WO 92/22578 PCT/SE92/0039~ ':
g Step 2: Further purification of cSCMC fraction PSCMC fraction was dissolved in 8 mg/ml H20. SO~,tl of.sampla (0.4 mg) was mixed with 450 ~l O.iX TFA in water and applied on a FPLC coupled Pep RPC HR5/5 (Pharmacia). The column was washed with O.iX TFA in H20 for 10 min. at a flow rate of 0.5 ml/min. Then the acetonitrile concentration was raised to 27X
in 5 min. The~active material was eluted with a gradient of 27X-32X acetonitrile in 34 min. An aliquot t50 ~.tl or i00 ~1) of each fraction was dried in the Spesdvac and dissolved in i0 10~.t1 H20 and 3 ~1 was used in an antibacterial assay.
Result: The active material was eluted at 28.5X acetonitrils under tt-.e chosen gradient profile. On the appended drawing there is shown,a diagram on antibacterial activity (E.coli) i5 as a function of elut3on.tims. As a test sample there was used 0 . 4 mg of the purif isd active f raction in 50 Etl H20 mixed with 450 ~.tl of O.iX TFA in H20. The sample was applied to Pep RPC HR5/5 coupled to FPLC. The elution program was as follows:
dime X~acetonitrzle i5 27 Antibacterial assay The antibacterial activity of the polypeptide of this invention was determined by inhibition zone assay as descri-bed by Hultmark et al. (Hultmark, D., ~ngstrom, A., Anderson, K., Steiner, H., Hennich, H. and Homan, H.G. C1983). Inswct immunity. Attacins, a family of antibacterial proteins from a cec-"rooia . EMBO J . 2 , 571-576 ) .
SUBSTITUTE SHEET
Log-phase bacteria were grown to a density of 100 units on a Klett-summerson photoelectric colorimeter. Thev were diluted 50 times with LB medium and 50 ~l of the bacteria suspension was mixed with 6 ml of 1.0% agarose in LB medium (w/v) and poured on the petri dishes (Falcon 1001 Optilux*) with inner diameter 8.65 cm. For E.coli this procedure will give about 2 x 105 bacteria per plate.
The plates were left for 1 hour at room temperature, and holes with 3mm diameter were made on the solidified agarose. 100 ~l of fractions were dried in a speedvac and dissolved in 10 ~1 H20, of which 3 ~1 was applied to the holes. After 30 min diffusion time the plates were incubated at 30°C overnight. The diameter of the inhibition zones were measured and the relative unit activity was calculated from a standard curve which was constructed on varying amount of Cecropin A versus activity.
One microgram of Cecropin A corresponds to 1000 units of activity.
The anti-E.coli activity of PS CMC fractions Fraction No. Specific activity (units/~g) PS CMC Fr. I 0.5 PS CMC Fr. II 0_7 PS CMC Fr. III 1.4 PS CMC Fr. IV 2.0 PS CMC Fr. V 14.0 PS CMC Fr. VI 84.0 PS CMC Fr. VII 100.0 *Trademark WO 92/22578" 1 1 ~ 3 4 ~ pCT/5E92/003~
The anti-E c~~~ ~~t:~:tyof fractions collected from the re-vs~~ a n11~:~ f~hrn~nwtneran1v of PS CMC Fr. VII On a FPLC COllD"
led Pe~RPC HR5/5 column.
Frac tion No. ~ Unit activity/traction Fr. i-8 activity not detestable Fr. 9 8400 Fr. i0 28000 Fr. ii 28000 Fr. 12 13000 Fr. 13 7300 Fr. i4 3500 Fr. i5 1100 Fr. 16-30 activity not detectable In this test 400 E,tg PS CMC Fr. VII was applied to the column.
Example 3 was rspeated by using $~,il.lus meaaterium for measuring the antibacterial activity of the present poly-peptide. The experiment has shown that Hacil~ug meaaiterium is more sensitive than coli to the peptide,~the average acti-vity of the polypeptide being about 3 times higher than in relation to ~'.,~coli.
SUBSTITd.lTF SHEET
__ _--~_ .~~~~....~~......w.............'.<.,......e~wmP~r.mr..K.eam~nxn~.<a.mc...
.~.r, eu.<,h... x~.. !..as .,5~4~:k4~....~AntP'.'S'.-r~'v~y~.,.,..i.rs(k:.;a5'f'~S' . 41n 1 1S. , ...a.. ,. ,.... . ' ' ~ ~ ~ ~ ~ ~ ~ PCT/SE92/00394 9 :,~. .
inhibition zone otide on di,~fe rent bacteria assay of PR-ne Qraanism Strain bax zone fm m) L,C value tuM) Escherichia coli K12 D21 18,3 0,3 Eschericliia coli Bd2221/75 0,3 17,6 Salmonella typhimurium L12 15,2 1 Proteus vulgaris Pvii - 3,5 300 Pseudomones aeruginose OT97 4,5 200 Acinetobacter '- calcoaceticus Acii 12,5 3 i5 Bacillus megaterium Hmii 17,4 0,3 Bacillus subtilis 10,3 15 Hsii Staphylococcus aureus Cowan 1 3,7 200 Streptococcus - pyrogenes - 14,9 2 The maximum concentration ide was 2,5 mM
of PR-pept and 3~1 was applied to each well in thin agaros e plates seeded with test bacte rium. LV values from a dilution are obtained aerie and is th e lowest concentration givin g killing tHultmark, D., Engstrom, Anderson, K., Steiner, H., A., Hennich, H. and Boman, H.G. (19a3)) SUBSTITUTE SHEET
Claims (8)
1. A polypeptide comprising the following amino acid sequence:
Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro, and antibacterially active derivatives thereof, the derivatization being constituted by conservative substitution of aminoacids or C-terminal amidation, or both conservative substitution of aminoacids and C-terminal amidation.
Arg-Arg-Arg-Pro-Arg-Pro-Pro-Tyr-Leu-Pro-Arg-Pro-Arg-Pro-Pro-Pro-Phe-Phe-Pro-Pro-Arg-Leu-Pro-Pro-Arg-Ile-Pro-Pro-Gly-Phe-Pro-Pro-Arg-Phe-Pro-Pro-Arg-Phe-Pro, and antibacterially active derivatives thereof, the derivatization being constituted by conservative substitution of aminoacids or C-terminal amidation, or both conservative substitution of aminoacids and C-terminal amidation.
2. Polypeptide according to claim 1, in an underivatized form.
3. Polypeptide according to claim 1 or 2 for therapeutic use.
4. Polypeptide according to claim 3 for use as an antibacterial agent.
5. A pharmaceutical composition containing as an active constituent the polypeptide according to claim 1 or 2 in an antibacterially effective amount together with a pharmaceutically acceptable carrier or diluent.
6. A pharmaceutical composition according to claim 5, wherein said carrier or diluent is acceptable for oral, intramuscular, intravenous or subcutaneous administration.
7. Use of a polypeptide according to claim 1 or 2 as an antibacterial agent.
8. Use of a polypeptide according to claim 1 or 2 in the manufacture of a pharmaceutical composition for use as an antibacterial agent.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9101838-2 | 1991-06-14 | ||
| SE9101838A SE468516B (en) | 1991-06-14 | 1991-06-14 | NEW POLYPEPTIDES WHICH CAN BE OBTAINED FROM THE TIN GAS AND THEIR USE |
| PCT/SE1992/000394 WO1992022578A1 (en) | 1991-06-14 | 1992-06-10 | Novel polypeptides and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2111340A1 CA2111340A1 (en) | 1992-12-23 |
| CA2111340C true CA2111340C (en) | 2002-08-20 |
Family
ID=20383046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002111340A Expired - Fee Related CA2111340C (en) | 1991-06-14 | 1992-06-10 | Novel polypeptides and their use |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5489575A (en) |
| EP (1) | EP0589995B1 (en) |
| JP (1) | JP3532917B2 (en) |
| AT (1) | ATE178072T1 (en) |
| AU (1) | AU667472B2 (en) |
| CA (1) | CA2111340C (en) |
| DE (1) | DE69228749T2 (en) |
| DK (1) | DK0589995T3 (en) |
| ES (1) | ES2131528T3 (en) |
| GR (1) | GR3029887T3 (en) |
| SE (1) | SE468516B (en) |
| WO (1) | WO1992022578A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0665239A1 (en) * | 1994-01-26 | 1995-08-02 | Consiglio Nazionale Delle Ricerche | Peptide derivatives of bactenecin endowed with antibacterial activity |
| US5654273A (en) * | 1994-09-22 | 1997-08-05 | Children's Medical Center Corporation | Synducin mediated modulation of tissue repair |
| US6133233A (en) * | 1997-02-18 | 2000-10-17 | Kansas State University Research Foundation | Peptide modulation of reperfusion injury |
| EP1019070A4 (en) * | 1997-04-23 | 2001-05-16 | Univ Michigan | Bradykinin analogs as selective inhibitors of cell activation |
| US6982249B1 (en) | 1997-04-23 | 2006-01-03 | The Regents Of The University Of Michigan | Bradykinin analogs as selective inhibitors of cell activation |
| US7147633B2 (en) * | 1999-06-02 | 2006-12-12 | Boston Scientific Scimed, Inc. | Method and apparatus for treatment of atrial fibrillation |
| WO2000072908A1 (en) * | 1999-06-02 | 2000-12-07 | Microheart, Inc. | Devices and methods for delivering a drug |
| US6676679B1 (en) | 1999-11-05 | 2004-01-13 | Boston Scientific Corporation | Method and apparatus for recurrent demand injury in stimulating angiogenesis |
| CA2389863A1 (en) * | 1999-11-05 | 2001-05-10 | U. Hiram Chee | Method and apparatus for demand injury in stimulating angiogenesis |
| US6748258B1 (en) | 1999-11-05 | 2004-06-08 | Scimed Life Systems, Inc. | Method and devices for heart treatment |
| EP1242107A4 (en) * | 1999-12-29 | 2004-10-06 | Beth Israel Hospital | Method for pr-39 peptide mediated selective inhibition of ikappabalpha degradation |
| WO2001070117A2 (en) | 2000-03-23 | 2001-09-27 | Microheart, Inc. | Pressure sensor for therapeutic delivery device and method |
| US7214223B2 (en) * | 2000-03-24 | 2007-05-08 | Boston Scientific Scimed, Inc. | Photoatherolytic catheter apparatus and method |
| WO2002000278A2 (en) | 2000-06-26 | 2002-01-03 | Microheart, Inc. | Method and apparatus for treating ischemic tissue |
| US20020065397A1 (en) | 2000-10-12 | 2002-05-30 | Joseph Roberts | Protecting therapeutic compositions from host-mediated inactivation |
| NZ545815A (en) * | 2003-09-12 | 2009-11-27 | Novozymes As | Synthetic antimicrobial polypeptides |
| US7250398B2 (en) | 2003-09-12 | 2007-07-31 | Novozymes A/S | Synthetic antimicrobial polypeptides |
| JP2007314432A (en) * | 2006-05-23 | 2007-12-06 | Japan Science & Technology Agency | New antimicrobial peptide and serum-free medium containing the antimicrobial peptide as active ingredient |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0375724B1 (en) * | 1987-08-11 | 1995-05-31 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
| SE469132B (en) * | 1989-06-16 | 1993-05-17 | Kabigen Ab | POLYPEPTIDES AND PHARMACEUTICAL COMPOSITION CONTAINING THIS |
-
1991
- 1991-06-14 SE SE9101838A patent/SE468516B/en not_active IP Right Cessation
-
1992
- 1992-06-10 AU AU20220/92A patent/AU667472B2/en not_active Ceased
- 1992-06-10 DK DK92912631T patent/DK0589995T3/en active
- 1992-06-10 JP JP50081893A patent/JP3532917B2/en not_active Expired - Fee Related
- 1992-06-10 WO PCT/SE1992/000394 patent/WO1992022578A1/en active IP Right Grant
- 1992-06-10 DE DE69228749T patent/DE69228749T2/en not_active Expired - Fee Related
- 1992-06-10 US US08/162,052 patent/US5489575A/en not_active Expired - Fee Related
- 1992-06-10 EP EP92912631A patent/EP0589995B1/en not_active Expired - Lifetime
- 1992-06-10 ES ES92912631T patent/ES2131528T3/en not_active Expired - Lifetime
- 1992-06-10 CA CA002111340A patent/CA2111340C/en not_active Expired - Fee Related
- 1992-06-10 AT AT92912631T patent/ATE178072T1/en not_active IP Right Cessation
-
1999
- 1999-04-05 GR GR990400977T patent/GR3029887T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022092A (en) | 1993-01-12 |
| DK0589995T3 (en) | 1999-07-19 |
| AU667472B2 (en) | 1996-03-28 |
| CA2111340A1 (en) | 1992-12-23 |
| JPH07502013A (en) | 1995-03-02 |
| EP0589995B1 (en) | 1999-03-24 |
| SE468516B (en) | 1993-02-01 |
| GR3029887T3 (en) | 1999-07-30 |
| JP3532917B2 (en) | 2004-05-31 |
| US5489575A (en) | 1996-02-06 |
| DE69228749T2 (en) | 1999-07-22 |
| EP0589995A1 (en) | 1994-04-06 |
| SE9101838L (en) | 1992-12-15 |
| ES2131528T3 (en) | 1999-08-01 |
| DE69228749D1 (en) | 1999-04-29 |
| WO1992022578A1 (en) | 1992-12-23 |
| SE9101838D0 (en) | 1991-06-14 |
| ATE178072T1 (en) | 1999-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2111340C (en) | Novel polypeptides and their use | |
| US6008195A (en) | Antimicrobial peptides and methods of use | |
| US5585353A (en) | Antibiotic peptides containing D-amino acids | |
| Ishikawa et al. | Purification and characterization of a diptericin homologue from Sarcophaga peregrina (flesh fly) | |
| CA2018461C (en) | Novel polypeptides and their use | |
| CA2220854A1 (en) | Anti-ulcer composition | |
| Conlon et al. | Isolation of a peptide structurally related to mammalian corticostatins from the lamprey Petromyzon marinus | |
| KR101847051B1 (en) | Antibiotic peptides having an antibiotics and comprising antibiotic composition thereof | |
| JPH08165248A (en) | Endotoxin-derived inflammation inhibitor | |
| EP1238058B1 (en) | Use of colostrinin, constituent peptides and analogs thereof to promote neural cell differentiation | |
| US6852685B1 (en) | Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neuronal cell differentiation | |
| JP3106191B1 (en) | Physiological function controlling peptide of FGF-5 and pharmaceutical composition containing the peptide | |
| JPH05504069A (en) | Type 1 New mutants derived from interferon, their production methods and their applications | |
| EP2332964B1 (en) | Apoptotically active peptides | |
| US5529792A (en) | Inhibitors of endothelial cell proliferation | |
| WO1994007518A1 (en) | Anaphylatoxin receptor ligands containing lipophilic residues | |
| WO2002013851A1 (en) | Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neural cell differentiation | |
| US5981469A (en) | 78 residue polypeptide (NK-lysine) and its use | |
| JPH07309771A (en) | Parenteral antitumor agent | |
| KR0149278B1 (en) | Bacteriocidal peptide from korean bufo bufo gargarizans | |
| CA2079291A1 (en) | Activities of heparin binding neurite-outgrowth promoting factor | |
| JPH0653759B2 (en) | Method for producing tumor cell growth inhibitory and tumoricidal cell factors | |
| CZ20032744A3 (en) | Use of the protein uk114 or of fragments thereof for the treatment and prevention of the endotoxic shock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |